These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31693942)

  • 21. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.
    Gouin-Thibault I; Flaujac C; Delavenne X; Quenet S; Horellou MH; Laporte S; Siguret V; Lecompte T
    Thromb Haemost; 2014 Feb; 111(2):240-8. PubMed ID: 24172843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analytical and between-subject variation of thrombin generation measured by calibrated automated thrombography on plasma samples.
    Kristensen AF; Kristensen SR; Falkmer U; Münster AB; Pedersen S
    Scand J Clin Lab Invest; 2018 May; 78(3):175-179. PubMed ID: 29336181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers.
    Cheung YW; Barco S; Hutten BA; Meijers JC; Middeldorp S; Coppens M
    J Thromb Haemost; 2015 Oct; 13(10):1799-805. PubMed ID: 26270625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
    Kreutz R; Persson PB; Kubitza D; Thelen K; Heitmeier S; Schwers S; Becka M; Hemmrich M
    J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.
    Samama MM; Mendell J; Guinet C; Le Flem L; Kunitada S
    Thromb Res; 2012 Apr; 129(4):e77-82. PubMed ID: 21851967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Betrixaban: Impact on Routine and Specific Coagulation Assays-A Practical Laboratory Guide.
    Siriez R; Evrard J; Dogné JM; Pochet L; Gheldof D; Chatelain B; Mullier F; Douxfils J
    Thromb Haemost; 2018 Jul; 118(7):1203-1214. PubMed ID: 29890519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers.
    Nagalla S; Thomson L; Oppong Y; Bachman B; Chervoneva I; Kraft WK
    Clin Transl Sci; 2016 Jun; 9(3):176-80. PubMed ID: 27170068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
    Song Y; Wang Z; Perlstein I; Wang J; LaCreta F; Frost RJA; Frost C
    J Thromb Haemost; 2017 Nov; 15(11):2125-2137. PubMed ID: 28846831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonists.
    Honda Y; Morishima Y
    Thromb Res; 2015 May; 135(5):958-62. PubMed ID: 25791908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram.
    Machlus KR; Colby EA; Wu JR; Koch GG; Key NS; Wolberg AS
    Thromb Haemost; 2009 Nov; 102(5):936-44. PubMed ID: 19888532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents.
    van Veen JJ; Gatt A; Bowyer AE; Cooper PC; Kitchen S; Makris M
    Int J Lab Hematol; 2009 Apr; 31(2):189-98. PubMed ID: 18190585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of pre-analytical variables in a commercial thrombin generation assay.
    Rodgers SE; Wong A; Gopal RD; Dale BJ; Duncan EM; McRae SJ
    Thromb Res; 2014 Jul; 134(1):160-4. PubMed ID: 24792772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
    Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
    Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of apixaban anti-factor Xa assay and impact of body weight.
    Wasan SM; Feland N; Grant R; Aston CE
    Thromb Res; 2019 Oct; 182():51-55. PubMed ID: 31450008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
    Gosselin R; Grant RP; Adcock DM
    Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma.
    Conversy B; Blais MC; Dunn M; Gara-Boivin C; Carioto L; del Castillo JR
    Vet J; 2013 Nov; 198(2):437-43. PubMed ID: 24053991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide.
    Douxfils J; Chatelain C; Chatelain B; Dogné JM; Mullier F
    Thromb Haemost; 2013 Aug; 110(2):283-94. PubMed ID: 23765180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apixaban decreases brain thrombin activity in a male mouse model of acute ischemic stroke.
    Bushi D; Chapman J; Wohl A; Stein ES; Feingold E; Tanne D
    J Neurosci Res; 2018 Aug; 96(8):1406-1411. PubMed ID: 29761540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests.
    Tobu M; Iqbal O; Hoppensteadt DA; Shultz C; Jeske W; Fareed J
    Clin Appl Thromb Hemost; 2002 Oct; 8(4):325-36. PubMed ID: 12516682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.